title: Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome.
authors.affiliation: Department of Cardiology, Angiology and Pulmology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. e.chorianopoulos@med.uni-heidelberg.de
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Chorianopoulos
authors.forename: Kai
authors.initials: K
authors.lastname: Jarr
authors.forename: Henning
authors.initials: H
authors.lastname: Steen
authors.forename: Evangelos
authors.initials: E
authors.lastname: Giannitsis
authors.forename: Norbert
authors.initials: N
authors.lastname: Frey
authors.forename: Hugo A
authors.initials: HA
authors.lastname: Katus
mesh_terms: D000208:Acute Disease; D000368:Aged; D056988:Anterior Wall Myocardial Infarction / Q000503:physiopathology*; D003324:Coronary Artery Disease / Q000503:physiopathology; D000074049:Cytokine TWEAK; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D048069:Tumor Necrosis Factors / Q000097:blood*; D015854:Up-Regulation
chemical_list: D000074049:Cytokine TWEAK; C109743:TNFSF12 protein, human; D048069:Tumor Necrosis Factors